Stacy L. Moulder, M.D., M.S.C.I.
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Early Drug Development Clinical Trial Design Determining Pathways of Drug Resistance in Breast Cancer
Click here for the most up-to-date list of Dr. Moulder's publications.
Education & Training
Degree-Granting Education
| 2002 | Vanderbilt University, Nashville, TN, USA, MS, Masters of Science in Clinical Investigation |
| 1995 | University of Mississippi School of Medicine, Jackson, MS, USA, MD, Medicine |
| 1990 | Mississippi State University, Jackson, MS, USA, BS, Chemistry |
Postgraduate Training
| 1998-2001 | Clinical Fellowship, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN |
| 1995-1998 | Internship and Residency, Internal Medicine, University of Mississippi Medical Center, Jackson, MS |
Board Certifications
| 2002 | American Board of Internal Medicine, Medical Oncology |
| 1998 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2017
Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2012
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2010
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2010
Assistant Professor, Department of Comprehensive Breast Program, Interdisciplinary Oncology, Division of Cancer Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, 2002 - 2005
Administrative Appointments/Responsibilities
Co-Program Leader, "Learning From the Patient", The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018
Co-Program Leader, Moon Shots Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Chief, Section of Clinical Research and Drug Development, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017
Associate Clinical Medical Director, Breast Center, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2014
Chair, Department of Clinical Research Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011
Director, Department of Clinical Research / Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2004 - 2005
Other Appointments/Responsibilities
Planning Committee, Southwest Oncology Group, Houston, TX, 2012 - Present
Planning Committee, American College of Surgeons Oncology Group, Houston, TX, 2008 - 2009
Planning Committee, Translational Breast Cancer Research Consortium, Houston, TX, 2008 - Present
Clinical Investigations Steering Committee, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2004 - 2005
Hematology/Oncology Fellowship Research and Academic Mentor Committee, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2003 - 2005
Protocol Review and Monitoring Committee, Moffitt Cancer Center, Tampa, FL, 2002 - 2005
Institutional Committee Activities
Member, SWOG Triple Negative Working Group, 2011 - Present
Member, Breast Medical Oncology Personalized Medicine Committee, 2011 - Present
Planning Committee, Breast Cancer Clinical Research Seminar, 2009 - 2009
Chair, Breast Cancer Serum/DNA Bank Oversight Committee, 2008 - 2009
Member, Internal Review Board, 2008 - 2011
Member, Breast Cancer Tumor Bank Committee, Department of Breast Medical Oncology, 2007 - 2008
Member, Serum Bank Committee, Department of Breast Medical Oncology, 2006 - Present
Member, Clinical Research Committee, 2006 - 2008
Chair, Clinical Research Committee, 2005 - 2011
Honors & Awards
| 2002 | Career Development Award, American Society of Clinical Oncology |
| 2001 | Fellowship Award, American Association for Cancer Research |
| 2001 | Trainee Travel Award, American Society of Clinical Investigation |
| 2001 | Merit Award, American Society of Clinical Oncology |
| 2001 | Star Fellow Award, Vanderbilt Hematology Oncology |
| 2000 | Star Fellow Award, Vanderbilt Hematology Oncology |
| 1998 | Harry Joyce Fellowship, Vanderbilt University Medical Center |
| 1994 | Associated Student Body Vice President, University of Mississippi School of Medicine |
| 1992 | Medical Student Research Fellowship, University of Mississippi Medical Center |
Selected Publications
Peer-Reviewed Articles
- Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38(5):JCO1901304, 2020. e-Pub 2019. PMID: 31461380.
- Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel) 11(12), 2019. e-Pub 2019. PMID: 31835495.
- Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat 176(1):227-234, 2019. e-Pub 2019. PMID: 30977027.
- Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
- Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114:167-174, 2019. e-Pub 2019. PMID: 31005169.
- Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
- Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Wu Y, Alvarez MJ, Califano A, Moulder SL, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med 11(488), 2019. PMID: 30996079.
- Shinn EH, Broderick G, Fellman B, Johnson A, Wieland E, Moulder S, Symmans WF. Simulating Time-Dependent Patterns of Nonadherence by Patients With Breast Cancer to Adjuvant Oral Endocrine Therapy. JCO Clin Cancer Inform 3:1-9, 2019. PMID: 31002563.
- Carter S, Neuman H, Mamounas EP, Bedrosian I, Moulder S, Montero AJ, Jagsi R. Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Am Soc Clin Oncol Educ Book 39:42-48, 2019. e-Pub 2019. PMID: 31099648.
- Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
- Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
- Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
- Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Qiu H, Shao J, Jeter-Jones SL, Zhang X, Ramamoorthy V, Cai S, Wu W, Draetta G, Moulder SL, Symmans WF, Chang JT, Heffernan TP, Piwnica-Worms H. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun 9(1):5079, 2018. e-Pub 2018. PMID: 30498242.
- Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell 71(4):606-620.e7, 2018. PMID: 30118680.
- Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat 170(1):101-109, 2018. e-Pub 2018. PMID: 29470805.
- Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
- Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL. Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book(38):65-77, 2018. PMID: 30231328.
- Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
- Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 29(3):669-680, 2018. PMID: 29342248.
- Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol 13(1):21-38, 2018. PMID: 29218622.
- Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118(1):17-23, 2018. e-Pub 2017. PMID: 29235566.
- Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, Scott KL, Edwards JR, Liang H, Heffernan TP, Piwnica-Worms H. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ Breast Cancer 4:9, 2018. e-Pub 2018. PMID: 29736411.
- Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 28(10):2420-2428, 2017. PMID: 28961844.
- Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004-2009, 2017. e-Pub 2017. PMID: 28819400.
- Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple negative breast cancer. Clin Cancer Res 22(1):26-33, 2016. e-Pub 2015. PMID: 26286912.
- Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer 121(24):4324-32, 2015. e-Pub 2015. PMID: 26348887.
- Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33(4):890-4, 2015. e-Pub 2015. PMID: 25947565.
- DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The neoadjuvant model is still the future for drug development in breast cancer. Clin Cancer Res 21(13):2911-5, 2015. e-Pub 2015. PMID: 25712686.
- Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat 152(2):347-56, 2015. e-Pub 2015. PMID: 26109346.
- Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget 6(15):12890-908, 2015. e-Pub 2015. PMID: 25973541.
- Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
- Abouharb S, Moulder S. Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy. Curr Oncol Rep 17(3):431, 2015. PMID: 25691085.
- Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33(1):177-86, 2015. e-Pub 2014. PMID: 25323060.
- Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer 15(1):442, 2015. e-Pub 2015. PMID: 26021831.
- Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2(6):576-80, 2015. e-Pub 2015. PMID: 26244164.
- de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I Unit. Clin Breast Cancer 14(6):468-74, 2014. e-Pub 2014. PMID: 25065564.
- Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple negative breast cancer patients treated at MD Anderson Cancer Center in Phase I Trials: Improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175-84, 2014. e-Pub 2014. PMID: 25253784.
- Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res 20(20):5265-71, 2014. e-Pub 2014. PMID: 25172932.
- Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 2014. e-Pub 2014. PMID: 25038877.
- Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 2014. e-Pub 2014. PMID: 24677057.
- Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 2014. e-Pub 2014. PMID: 24752867.
- Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer . Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
- Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: Implications for clinical practice. Oncologist 19(5):453-8, 2014. e-Pub 2014. PMID: 24710307.
- Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 2014. e-Pub 2014. PMID: 24811890.
- Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 2014. PMID: 24912489.
- Advani PS, Ying J, Theriault R, Melhem-Bertrand A, Moulder S, Bedrosian I, Tereffe W, Black S, Pini TM, Brewster AM. Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer 120(6):894-900, 2014. e-Pub 2013. PMID: 24258799.
- Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 2014. e-Pub 2014. PMID: 24435060.
- Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Rep 6(2):377-87, 2014. e-Pub 2014. PMID: 24440717.
- Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 2013. e-Pub 2013. PMID: 23907406.
- Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: Final results of a phase I trial. Clin Cancer Res 19(19):5474-84, 2013. PMID: 24089446.
- Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res 19(17):4824-31, 2013. e-Pub 2013. PMID: 23873691.
- Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 31(4):918-26, 2013. e-Pub 2012. PMID: 23179336.
- Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol 31(20):e360-3, 2013. e-Pub 2013. PMID: 23733774.
- Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 2013. e-Pub 2012. PMID: 23053261.
- Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 2013. e-Pub 2012. PMID: 23242617.
- Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: Characteristics and outcomes. Oncotarget 3(12):1566-75, 2012. PMID: 23248156.
- Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the anti-angiogenic antibody bevacizumab and the mTOR / hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin. Clin Cancer Res 18(20):5796-805, 2012. e-Pub 2012. PMID: 22927482.
- Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs 30(5):1942-9, 2012. e-Pub 2011. PMID: 21931969.
- Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 2012. e-Pub 2011. PMID: 22006179.
- Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clin Cancer Res 18(10):2922-9, 2012. e-Pub 2012. PMID: 22452943.
- Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
- Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11(2):308-16, 2012. e-Pub 2011. PMID: 22203732.
- Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal Doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17(21):6840-6, 2011. e-Pub 2011. PMID: 21890452.
- Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128(3):783-94, 2011. e-Pub 2011. PMID: 21655990.
- Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol 29(19):e572-5, 2011. e-Pub 2011. PMID: 21482991.
- Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel in cancer patients with predominant hepatic metastases: Toxicity, pharmacokinetics, and activity. Mol Cancer Ther 10(7):1300-7, 2011. e-Pub 2011. PMID: 21571911.
- Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
- Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 10(1):209-17, 2011. PMID: 21220503.
- Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 2010. e-Pub 2010. PMID: 20204368.
- Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 28(5):634-40, 2010. e-Pub 2009. PMID: 19499186.
- Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9(5):1120-7, 2010. e-Pub 2010. PMID: 20423993.
- Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2010. PMID: 20052721.
- Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 119(3):663-71, 2010. PMID: 20012354.
- Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center experience. Clin Breast Cancer 10(1):46-51, 2010. PMID: 20133258.
- Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin e can bypass letrozole-induced g1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16(4):1179-90, 2010. e-Pub 2010. PMID: 20145171.
Invited Articles
- Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol 23 Suppl 10:x231-6, 2012. PMID: 22987968.
- Moulder SL. Does the PI3K pathway play a role in basal breast cancer?. Clin Breast Cancer 10:S66-71, 2010. PMID: 21115424.
- Moulder SL. Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl) 6(6):821-30, 2010. PMID: 21118040.
- Moulder SL. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clin Breast Cancer 10:S30-40, 2010. PMID: 20805063.
Abstracts
- Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, Symmans WF, Draetta GF, Futrea Al, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). J Clin Oncol 27(15):suppl; abstr # 586, 2019.
- Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. J Clin Oncol 27(15):suppl; abstr # 10507, 2019.
- Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. J Clin Oncol 27(15):suppl; abstr # 572, 2019.
- Wulfkuhle JD, Wolf DM, Yau C, Gallager RI, Brown Swigart L, Hirst GL, Yee D, Raffin Pohlmann P, Elias AD, Moulder SL, Tripathy D, DeMichele A, Esserman L, Berry DA, vant' Veer L, Petricoin E, I-SPY 2 Investigators. HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 trial. J Clin Oncol 27(15):suppl; abstr # 3133, 2019.
- Bardia A, Hurvitz SA, DeMichele A, Sanders Clark A, Zelnak AB, Yardley DA, Karuturi MS, Sanft TB, Blau S, Hart, Ma CX, Caria N, Das D, Purkayastha D, Mistry A, Moulder SL. Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2-advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. J Clin Oncol 27(15):suppl; abstr # 1016, 2019.
- Moulder SL, Hess KR, Candelaria RP, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murth RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 36(15):suppl; abstr # 518, 2018.
- Yam C, Hess KR, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). J Clin Oncol 36(15):suppl; abstr # 593, 2018.
- Litton, JK, Scoggins M, Hess KR, Adrada B, Barcenas CH, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, Arun B. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). J Clin Oncol 35(15):suppl; abstr # 508, 2018.
- Westin SN, Litton JK, Williams RA, Shepherd CJ, Brugger W, Pease EJ, Soliman PT, Frumovitz MM, Levenback CF, Sood A, Meyer L, Moulder SL, Valero V, Saleem S, Rodriguez AM, Cyriac A, Engerman L, Samuel C, Mills GB, Coleman RL. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. J Clin Oncol 36(15):suppl; abstr # 5504, 2018.
- Basho RK, Trevarton A, Hess KR, Fu C, Lau R, Lin CH, Lichtarge O, Yang WT, Symmans WF, Moulder SL. Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). J Clin Oncol 36(15):suppl; abstr # 588, 2018.
- Baez Vallecillo LB, Chang JT, Chen K, Moss TJ, Shaw KR, Meric-Bernstam F, Eterovic AK, Mills GB, Mani S, Li XB, Gilcrease M, Moulder SL. Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival. J Clin Oncol 35(15):suppl; abstract #1090, 2017.
- Finn RS, Dieras V, Rugo HS, Joy AA, Moulder SL, Walshe JM, Mukai H, Shparyk YV. Palbociclib (PAL+ letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups. J Clin Oncol 35(15):suppl; abstr # 1039, 2017.
- Finn RS, Martin M, Rugo HS, Jones SE, Im SA, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D, Randolph S, Dieras V, Slamon DJ. PALOMA-2: Primary results from a phase III trial of Palbociclib plus Letrozole compared with Placebo plus Letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. J Clin Oncol 34(15):suppl; abstr # 507, 2016.
- Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Moulder SL, Luthra J, Lee J, Tsimberidou AM, Korzrock R. Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibits. J Clin Oncol 29(15):suppl; abstr # 10507, 2011. PMID: 28022381.
Grant & Contract Support
| Title: | The use of DNA microarray to determine pathways of metastasis, immune modulation and resistance to therapy in breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | Using DNA microarray to determine future targets for breast cancer therapy |
| Funding Source: | Business and Professional Women of Texas |
| Role: | Principal Investigator |
| Title: | A single arm phase II study of gemcitabine and irinotecan in patients with metastatic breast cancer |
| Funding Source: | National Comprehensive Cancer Network (NCCN) |
| Role: | Principal Investigator |
| Title: | Targeting the EGF family of receptors for breast cancer therapy |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Vanderbilt-Ingram Cancer Center Lung SPORE pilot project: Investigating endothelial cell precursors as potential therapeutic targets in lung cancer |
| Funding Source: | Vanderbilt-Ingram Cancer Center |
| Role: | Principal Investigator |
| Title: | Role of circulating endothelial cell precursors in tumor vascular formation |
| Funding Source: | American Association of Cancer Research and American Society of Clinical Oncology |
| Role: | Principal Investigator |
| Title: | LMW-E, a novel indicator of letrozole resistance in breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Investigator |
| Title: | Targeting the cell cycle in triple negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Validation and implementation of genomic testing for chemotherapy and endocrine sensitivity |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Investigator |
| Title: | Southwest Early Clinical Trials (SECT) Consortium |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Proposal for a partnership between the Translational Breast Cancer Research Consortium and the Susan G. Komen for the Cure Foundation |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Principal Investigator |
| Title: | Women’s triple-negative first-line study: A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT), including a lead in cohort to establish activity in patients with metastatic TNBC |
| Funding Source: | National Comprehensive Cancer Network (NCCN) |
| Role: | Principal Investigator |
| Title: | A randomized clinical trial platform with translational studies to overcome resistance in triple negative breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Translational Breast Cancer Research Consortium Infrastructure Support |
| Funding Source: | Johns Hopkins University |
| Role: | Principal Investigator-MDACC |
| Title: | Neoadjuvant triaging and therapeutic platform for treatment of localized triple negative breast cancer (TNBC) |
| Funding Source: | UT MD Anderson Cancer Center (Internal Funding: Women's Cancer Moonshot Breast) Annual Renewal |
| Role: | Principal Investigator |
| Title: | Moon Shot: Breast Cancer |
| Funding Source: | Still Water Foundation |
| Role: | Principal Investigator |
| Title: | Investigating the functional impact of TP53 mutations in triple negative breast cancer |
| Funding Source: | Oregon Health and Science University |
| Role: | Co-Investigator |
| Title: | Feasibility, validation and implementation of genomic testing for chemotherapy and endocrine sensitivity of HER2 negative primary invasive breast cancer (Clinical Stage I to III) |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Principal Investigator |
| Title: | ARTEMIS: A robust TNBC evaluation framework to improve survival |
| Funding Source: | The University of Texas MD Anderson Cancer Center, Institutional Funds: Breast Moonshot |
| Role: | Principal Investigator |
| Title: | A somatic mutant p53 mouse model of metastatic triple negative breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Task Order 2019: Translational Breast Cancer Research Consortium Infrastructure Support (Annual Renewal) |
| Funding Source: | John Hopkins University |
| Role: | Principal Investigator |
| Title: | Neoadjuvant treatment response monitoring of breast cancer with molecular photoacoustic imaging |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Task Order 2020: Translational Breast Cancer Research Consortium Infrastructure Support (Annual Renewal) |
| Funding Source: | John Hopkins University |
| Role: | Principal Investigator |